HC Surgical Specialists Limited Posts FY2026 Financial Results: Key Details and Investor Insights
Executive Summary
- Revenue: S\$19.38 million, up 1.4% from FY2025
- Profit Attributable to Shareholders: S\$6.98 million, down 17.2% from FY2025
- Total Dividend Proposed: S\$0.0208 per ordinary share (interim S\$0.009 + final S\$0.0118)
- Core Operations Remain Profitable
- Expansion of Specialist Services
Detailed Financial Analysis
Revenue and Profit Trends
HC Surgical Specialists Limited (“HCSS”) reported a marginal increase in revenue to S\$19.38 million for FY2026, representing a 1.4% year-on-year growth. However, profit attributable to shareholders declined by 17.2% to S\$6.98 million. Earnings per share dropped from 5.49 Singapore cents in FY2025 to 4.55 Singapore cents in FY2026, reflecting the lower profit base.
Reasons for Profit Decline
- Non-operational Items: The decrease in profits was attributed mainly to several non-operational factors:
- Fair value loss on derivative financial instruments (DFI) of S\$0.44 million (vs. gain of S\$1.46 million in FY2025)
- Loss allowance for trade and other receivables of S\$32,000 (vs. reversal of S\$4,000 in FY2025)
- Offset by fair value gain on financial assets at fair value through profit or loss (FVTPL) of S\$1.65 million (vs. S\$0.70 million in FY2025)
- No loss arising from deemed disposal in an associate (S\$0.21 million loss in FY2025)
- Increased share of results from associates and joint ventures (+S\$0.18 million)
- Higher income tax expense (+S\$0.42 million) due to lower tax rebates
- Other Income: Decreased by S\$0.14 million, mainly due to:
- Lower grants (-S\$0.16 million)
- Lower interest income (-S\$17,000)
- Absence of compensation income from GMH Endoscopy & Surgery Pte. Ltd. (-S\$0.14 million)
- Offset partially by increased consultancy fee income (+S\$0.20 million)
- Employee Benefits Expense: Increased by S\$0.76 million due to:
- Higher headcount
- Regular salary increments
- Higher bonus provisions
- Higher locum doctors’ fees
- Higher salaries from new subsidiary acquisition
- Finance Costs: Decreased by S\$0.15 million due to settlement of deferred consideration for previous acquisitions (Jason Lim Endoscopy and Surgery Pte. Ltd. and Total Orthopaedics Pte. Ltd.).
Investment Activity and Fair Value Changes
- Financial Assets at FVTPL: S\$1.65 million fair value gain mainly due to:
- Increase in share price of Medinex Limited (direct interest: 22.35%, deemed interest: 9.26%)
- Increase in share price of Aoxin Q & M Dental Group Limited (direct interest: 0.21%)
- Fair value gain on HSN Healthcare Pte. Ltd.
- Offset by decrease in share price of Singapore Paincare Holdings Limited (direct interest: 2.25%)
- Investment Disposals: S\$0.17 million gain on disposal of shares in SPCH and Aoxin.
- DFI Loss: S\$0.44 million fair value loss due to forward purchase contract for Total Orthopaedics Pte. Ltd.
- No deemed disposal loss: No similar loss in FY2026 as was seen in FY2025 (S\$0.21 million loss from Medistar Services Pte. Ltd.).
Dividend Announcement
The Board has recommended a final dividend of 1.18 Singapore cents, subject to shareholder approval. Combined with the interim dividend of 0.90 Singapore cents paid in March 2026, the total dividend for FY2026 will be 2.08 Singapore cents per ordinary share. This demonstrates the company’s ongoing commitment to rewarding shareholders despite a dip in annual profits.
Strategic Developments & Expansion
Specialist Recruitment
- April 2026: First hepatopancreatobiliary specialist, Dr. Lee Lip Seng, joins Chirurgia Pte. Ltd.
- July 2026: Dr. Ng Yi Kang, gastroenterologist and hepatologist, starts at NYK Endoscopy and Digestive Centre Pte. Ltd.
- The Group aims to broaden its spectrum of medical service offerings by recruiting more specialists.
CEO Statement
“FY2026 revenue remains consistent as compared to FY2025, as our core operations remained profitable. We will continue to focus on our core competencies and look for opportunities for expansion.” – Dr. Heah Sieu Min, CEO
The Group’s emphasis on nurturing the next generation of doctors and expanding specialist services is expected to drive future growth and enhance shareholder value.
Shareholder Considerations – Price Sensitive Information
- Significant decline in profit attributable to shareholders, mainly driven by non-operational fair value changes and higher employee costs. This may impact investor sentiment and share price.
- Strong dividend payout maintained, indicating management’s confidence in operational cash flows.
- Ongoing expansion and recruitment of new specialist doctors signal future growth opportunities but may attract higher operating expenses in the near term.
- Exposure to fair value changes in listed associates and financial instruments may continue to introduce volatility to reported earnings.
Corporate Profile
HCSS operates 19 clinics in Singapore, primarily focusing on endoscopic procedures (gastroscopies, colonoscopies) and general surgery with a specialisation in colorectal procedures.
Investor Contact & Compliance
- For further information, visit: www.hcsurgicalspecialists.com
- Investor Relations Contact: [email protected]
- This release has been reviewed by Novus Corporate Finance Pte. Ltd., but not approved by the Singapore Exchange.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Investors should conduct their own due diligence or consult their financial advisors before making investment decisions. HC Surgical Specialists Limited’s results and statements are subject to change and interpretation.
HC外科专科有限公司2026财年财务报告 – 投资者详细解读
主要亮点
- 收入：1,938万新元，同比增长1.4%
- 归属于股东的利润：698万新元，同比下降17.2%
- 总派息：每股0.0208新元（中期0.009新元+末期0.0118新元）
- 核心业务持续盈利
- 专科服务持续扩展
详细财务分析
收入与利润趋势
HC外科专科有限公司（“HCSS”）2026财年收入微增至1,938万新元，但归属于股东的利润下降至698万新元。每股收益从2025财年的5.49分降至2026财年的4.55分。
利润下降原因
- 非经营项目：利润下降主要源于以下因素：
- 衍生金融工具公允价值损失44万新元（2025年为146万新元的收益）
- 贸易及其他应收款项损失准备3.2万新元（2025年为0.4万新元准备转回）
- 部分被公允价值变动收益（FVTPL）165万新元（2025年为70万新元收益）抵消
- 无关联公司处置损失（2025年为21万新元损失）
- 联营及合营公司收益增加18万新元
- 所得税费用增加42万新元，因税收优惠减少
- 其他收入：减少14万新元，主要原因包括：
- 政府补助减少16万新元
- 利息收入减少1.7万新元
- 无GMH Endoscopy & Surgery Pte. Ltd.赔偿收入（2025年为14万新元）
- 部分被咨询费收入增加20万新元抵消
- 员工福利费用：增加76万新元，原因包括人员增加、薪资调整、奖金提高、兼诊医生费用及新收购子公司薪资增长。
- 财务成本：减少15万新元，因前期收购相关递延款项已结清。
投资活动与公允价值变动
- 金融资产公允价值变动：165万新元收益，主要源于：
- Medinex Limited股价上升（直接持有22.35%，间接9.26%）
- Aoxin Q & M Dental Group Limited股价上升（直接持有0.21%）
- HSN Healthcare Pte. Ltd.公允价值收益
- 部分被Singapore Paincare Holdings Limited股价下跌（直接持有2.25%）抵消
- 投资处置：处置SPCH及Aoxin股票获利17万新元。
- 衍生金融工具损失：44万新元，主要为TOPL前置购买合同公允价值重估。
- 无关联公司处置损失：2026年未出现2025年Medistar Services Pte. Ltd.相关损失。
分红公告
董事会提议末期派息1.18分（待股东大会批准），加上今年3月已派中期股息0.90分，2026财年总分红达2.08分/每股，显示公司对现金流及股东回报的信心。
战略发展与扩展
- 2026年4月：肝胰胆专科医生李立成加入Chirurgia Pte. Ltd.
- 2026年7月：肠胃及肝病专科医生黄义康加入NYK Endoscopy and Digestive Centre Pte. Ltd.
- 集团将继续引进更多专科医生，扩展医疗服务范围。
CEO观点
“2026财年收入与去年持平，核心业务持续盈利。我们将继续专注核心能力，寻求扩展机会。” – CEO许秀民医生
集团强调培养新一代医生、扩展专科服务，预计将带来未来增长并提升股东价值。
股东关注 – 价格敏感信息
- 归属于股东利润大幅下降，主要源于非经营性公允价值变动及员工成本上升，可能影响市场情绪和股价。
- 分红水平维持，显示管理层对经营现金流的信心。
- 专科医生持续招聘带来扩展机会，但短期内运营成本可能上升。
- 对上市联营公司及金融工具公允价值变动的敞口，未来利润波动性加大。
公司简介
HCSS在新加坡拥有19家诊所，主要提供胃肠镜检查和结直肠手术等专科服务。
投资者联系方式与合规说明
- 更多信息请访问：www.hcsurgicalspecialists.com
- 投资者关系邮箱：[email protected]
- 本公告已由Novus Corporate Finance Pte. Ltd.审阅，但未获新加坡交易所批准。
免责声明
本文章仅供参考，不构成投资建议或买卖证券的邀请。投资者应自行调查或咨询专业人士作出投资决策。HC外科专科有限公司业绩及陈述可能发生变化，解释权归公司所有。
